Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) shares gapped up prior to trading on Thursday after the company announced better than expected quarterly earnings. The stock had previously closed at $12.22, but opened at $12.56. Capricor Therapeutics shares last traded at $13.79, with a volume of 401,510 shares.
The biotechnology company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.15. The firm had revenue of $11.13 million for the quarter, compared to analyst estimates of $9.87 million. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%.
Analyst Ratings Changes
A number of brokerages have commented on CAPR. Cantor Fitzgerald restated an "overweight" rating and issued a $30.00 target price on shares of Capricor Therapeutics in a research note on Thursday. HC Wainwright reissued a "buy" rating and set a $77.00 target price on shares of Capricor Therapeutics in a report on Monday, March 17th. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. According to data from MarketBeat, Capricor Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $34.50.
Read Our Latest Analysis on CAPR
Institutional Trading of Capricor Therapeutics
Large investors have recently made changes to their positions in the stock. The Manufacturers Life Insurance Company acquired a new stake in Capricor Therapeutics in the 3rd quarter worth approximately $161,000. FMR LLC bought a new stake in shares of Capricor Therapeutics during the 3rd quarter worth $370,000. BNP Paribas Financial Markets grew its stake in Capricor Therapeutics by 868.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 17,699 shares of the biotechnology company's stock valued at $269,000 after buying an additional 15,872 shares during the last quarter. Fred Alger Management LLC acquired a new position in Capricor Therapeutics in the 3rd quarter valued at $399,000. Finally, PFM Health Sciences LP bought a new position in Capricor Therapeutics in the 3rd quarter worth $2,324,000. Institutional investors own 21.68% of the company's stock.
Capricor Therapeutics Stock Performance
The stock's 50-day simple moving average is $14.07 and its two-hundred day simple moving average is $14.76. The stock has a market cap of $603.84 million, a price-to-earnings ratio of -12.53 and a beta of 4.10.
About Capricor Therapeutics
(
Get Free Report)
Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
See Also
Before you consider Capricor Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Capricor Therapeutics wasn't on the list.
While Capricor Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
